Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
dba Hers September 09, 2025 FDA, accessed February 8, 2026, FDA Targets Hims & Hers, Other Marketers of Unapproved GLP-1 Weight-Loss Drugs, accessed February 8, 2026, 2025 PBM Satisfaction: Navigating Change and Opportunity in Pharmacy Benefit Management | Pharmaceutical Strategies Group (PSG), accessed February 8, 2026, Unchecked power in PBM industry puts patients at risk of harm, accessed February 8, 2026, The Future of PBMs in 2025: AI, Regulations, and Transparency Initiatives | Pharmacy Times, accessed February 8, 2026, Pharmacy Benefit Management PBM Market Outlook 2025-2032, accessed February 8, 2026, HIMS vs
It is NOT expected to be approved by the FDA until 2027 or 2028
SSK calibrated everything to my labs." "My recovery improved noticeably and my body composition shifted in a way Tirzepatide alone hadn't given me." "Sherry's involvement made the difference
In the experiment that led to discovery of GHK, plasma from young individuals added to liver tissue obtained from older individuals, caused old liver tissue to produce proteins more characteristic of younger individuals [6]
doi:10.1111/dom.15728 Regeneron Pharmaceuticals
For context, many diabetes medications struggle to achieve a 1% reduction
